Boston, Massachusetts, United States • 2 Employees
Research
Nivien Therapeutics developed the first LATS1/2 kinase inhibitors.https://www.washingtonpost.com/national/health-science/heres-what-happened-when-i-tried-to-develop-a-new-drug-for-a-deadly-cancer/2019/01/11/